Metastatic Nasopharyngeal Carcinoma
Conditions
Interventions
A:cisplatin+5-Fu+nimotuzumab
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Histologic diagnosis of nasopharyngeal carcinoma; 2. Distance metastasis at least 6 months after radical treatment; 3. Not suitable for local treatment, e.g. surgery, TACE; 4. At least one measurable lesion; 5. Estimate survival >3months; 6. Aged 18 to 70 years old; 7. PS 0~1; 8. WBC count >=4*10^9/L, Hemoglobin =100*10^9/L; 9. ALT or AST <2.5*ULN, bilirubin <1.5*ULN; 10. 0Serum creatinine <1.5*ULN.
Exclusion criteria
Exclusion criteria: 1. Central nervous system metastases; 2. Suitable for local treatment; 3. Second malignancy within 5 years; 4. Precious therapy with an investigational agent; 5. Uncontrolled seizure disorder or other serious neurologic disease; 6. >=Grade III allergic reaction to any drug including in this study; 7. Clinically significant cardiac or respiratory disease; 8. Creatinine clearance <30ml/min; 9. Drug or alcohol addition; 10. Do not have full capacity for civil acts; 11. Severe complication, active infection; 12. Concurrent immunotherapy or hormone therapy for other diseases; 13. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall objective rate;Progession-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of response;Time to progression;Overall survival;Toxicity;Quality of life; | — |
Countries
China
Contacts
Public ContactChong Zhao
Outcome results
None listed